COMMUNIQUÉS West-GlobeNewswire

Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
11/12/2017
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for [...]
Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
11/12/2017
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the first [...]
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
11/12/2017
Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel product under development for [...]
SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox
11/12/2017
– Company requests Priority Review of TPOXX NDA – – If approved, would be the first treatment for deadly smallpox – NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health [...]
Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis
11/12/2017
Study Presented at the 59 th American Society of Hematology (ASH) Annual Meeting Study focused on DLBCL (Diffuse Large B-Cell Lymphomas) RUTHERFORD, N.J., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq [...]
Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
11/12/2017
IRVING, Texas, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the presentation of interim data from [...]
Insider tradings
11/12/2017
Please see enclosed pdf.
Proposal of candidates to the Board of Directors
11/12/2017
The election of board members will be held at the Annual Shareholders’ Meeting on March 13, 2018, and the Board of Directors is today proposing candidates for that one-year term election. The Board of Directors is [...]
REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED
11/12/2017
Copenhagen, 2017-12-11 10:51 CET (GLOBE NEWSWIRE) -- This release does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, [...]
Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting
11/12/2017
Company announcement, Helsinki, 11 December 2017, at 9.00 AM Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting Nexstim Plc (NXTMH:HEX [...]
Galapagos to enter NASDAQ Biotech Index
11/12/2017
Mechelen, Belgium; 11 December 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces that it will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017. The NASDAQ Biotech Index (NBI [...]
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
11/12/2017
Workshop to be held on Monday, December 11 th at 12:00 pm EST December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
11/12/2017
Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the [...]
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
11/12/2017
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study 75% of ARGX-113 treated patients had a [...]
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency
11/12/2017
– Safety and Efficacy Profile Consistent with Previously Reported Data – – Hemoglobin Increases >1.0 g/dL in 26 of 52 Patients Overall; Responses Remain Durable with Completion of Six Month Core Treatment Period – – [...]
ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting
10/12/2017
– Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells – – Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 [...]
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
10/12/2017
At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4 neurologic events occurred in 12 [...]
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting
10/12/2017
CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its [...]
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
10/12/2017
39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 high patient population receiving G100+pembrolizumab (potential predictive biomarker) Responses occur in both recurrent/ [...]

Pages